Transient Hyperammonemic Encephalopathy in a Child with Relapsed Acute Lymphoblastic Leukemia and Severe Tumor Lysis Syndrome

Abstract

Idiopathic hyperammonemia (IHA) is a severe condition, which has been reported in intensive chemotherapy and bone marrow transplantation. This case elucidates the diagnostic dilemma in children undergoing initiation of chemotherapy and developing severe disorders of qualitative and quantitative consciousness in the presence of hyperammonemia (HA) and lactic acidosis. The role of mitoxantrone as a causative agent for IHA in children is elusive. Children undergoing chemotherapy are often in a poor general condition, and the clinical presentation of HA is heterogeneous. This case should be a reminder for clinicians to check for HA in children with tumor lysis syndrome and acute neurological deterioration.

Keywords

hyperammonemia - hyperammonemic encephalopathy - common acute lymphoblastic leukemia

Publication History

Received: 11 February 2021

Accepted: 14 June 2021

Article published online:
31 July 2021

• References

• 1 Auron A, Brophy PD. Hyperammonemia in review: pathophysiology, diagnosis, and treatment. Pediatr Nephrol 2012; 27 (02) 207-222
• 2 Davies SM, Szabo E, Wagner JE, Ramsay NK, Weisdorf DJ. Idiopathic hyperammonemia: a frequently lethal complication of bone marrow transplantation. Bone Marrow Transplant 1996; 17 (06) 1119-1125
• 3 Leonard JV, Kay JD. Acute encephalopathy and hyperammonaemia complicating treatment of acute lymphoblastic leukaemia with asparaginase. Lancet 1986; 1 (8473): 162-163
• 4 Nott L, Price TJ, Pittman K, Patterson K, Fletcher J. Hyperammonemia encephalopathy: an important cause of neurological deterioration following chemotherapy. Leuk Lymphoma 2007; 48 (09) 1702-1711
• 5 Mitchell RB, Wagner JE, Karp JE. et al. Syndrome of idiopathic hyperammonemia after high-dose chemotherapy: review of nine cases. Am J Med 1988; 85 (05) 662-667
• 6 Jaing T-H, Lin J-L, Lin Y-P, Yang S-H, Lin J-J, Hsia S-H. Hyperammonemic encephalopathy after induction chemotherapy for acute lymphoblastic leukemia. J Pediatr Hematol Oncol 2009; 31 (12) 955-956
• 7 Watson AJ, Chambers T, Karp JE, Risch VR, Walker WG, Brusilow SW. Transient idiopathic hyperammonemia in adults. Lancet 1985; 2 (8467): 1271-1274
• 8 Espinós J, Rifón J, Pérez-Calvo J, Nieto Y. Idiopathic hyperammonemia following high-dose chemotherapy. Bone Marrow Transplant 2006; 37 (09) 899-899
• 9 Ho AY, Mijovic A, Pagliuca A, Mufti GJ. Idiopathic hyperammonemia syndrome following allogeneic peripheral blood progenitor cell transplantation (allo-PBPCT). Bone Marrow Transplant 1997; 20 (11) 1007-1008
• 10 Tse N, Cederbaum S, Glaspy JA. Hyperammonemia following allogeneic bone marrow transplantation. Am J Hematol 1991; 38 (02) 140-141
• 11 Thomas SA, Tomeh N, Theard S. Fluorouracil-induced hyperammonemia in a patient with colorectal cancer. Anticancer Res 2015; 35 (12) 6761-6763
• 12 Snyder MJ, Bradford WD, Kishnani PS, Hale LP. Idiopathic hyperammonemia following an unrelated cord blood transplant for mucopolysaccharidosis I. Pediatr Dev Pathol 2003; 6 (01) 78-83
• 13 Lichtenstein GR, Yang Y-X, Nunes FA. et al. Fatal hyperammonemia after orthotopic lung transplantation. Ann Intern Med 2000; 132 (04) 283-287
• 14 Kobayashi S, Ito M, Sano H. et al. Idiopathic hyperammonemia that developed during initial treatment with steroid in a patient with newly diagnosed leukemia. J Pediatr Hematol Oncol 2015; 37 (06) e361-e363
• 15 Metzeler KH, Boeck S, Christ B. et al. Idiopathic hyperammonemia (IHA) after dose-dense induction chemotherapy for acute myeloid leukemia: case report and review of the literature. Leuk Res 2009; 33 (07) e69-e72
• 16 Rossato LG, Costa VM, Dallegrave E. et al. Mitochondrial cumulative damage induced by mitoxantrone: late onset cardiac energetic impairment. Cardiovasc Toxicol 2014; 14 (01) 30-40
• 17 Nickel RS, Keller F, Bergsagel J. et al. Mitoxantrone as a substitute for daunorubicin during induction in newly diagnosed lymphoblastic leukemia and lymphoma. Pediatr Blood Cancer 2014; 61 (05) 810-814
• 18 del Rosario M, Werlin SL, Lauer SJ. Hyperammonemic encephalopathy after chemotherapy. Survival after treatment with sodium benzoate and sodium phenylacetate. J Clin Gastroenterol 1997; 25 (04) 682-684
• 19 Jörck C, Kiess W, Weigel JFW, Mütze U, Bierbach U, Beblo S. Transient hyperammonemia due to L-asparaginase therapy in children with acute lymphoblastic leukemia or non-Hodgkin lymphoma. Pediatr Hematol Oncol 2011; 28 (01) 3-9
• 20 Heitink-Pollé KMJ, Prinsen BHCMT, de Koning TJ, van Hasselt PM, Bierings MB. High incidence of symptomatic hyperammonemia in children with acute lymphoblastic leukemia receiving pegylated asparaginase. In: Brown G, Morava E, Peters V, Gibson KM, Zschocke J. eds. JIMD Reports: Case and Research Reports, 2012/4. Vol 7. JIMD Reports. Springer Berlin Heidelberg; 2012: 103-108
• 21 Steiner M, Attarbaschi A, Kastner U. et al. Distinct fluctuations of ammonia levels during asparaginase therapy for childhood acute leukemia. Pediatr Blood Cancer 2007; 49 (05) 640-642
• 22 Stock W, Douer D, DeAngelo DJ. et al. Prevention and management of asparaginase/pegasparaginase-associated toxicities in adults and older adolescents: recommendations of an expert panel. Leuk Lymphoma 2011; 52 (12) 2237-2253
• 23 Peters M, Zee-Cheng J, Kuhl A, Orozco J, Lally E, Schwoerer JS. Pegylated asparaginase as cause of fatal hyperammonemia in patients with latent urea cycle disorder. Pediatr Blood Cancer 2018; 65 (09) e27239
• 24 Czogała M, Balwierz W, Sztefko K, Rogatko I. Clinical utility of ammonia concentration as a diagnostic test in monitoring of the treatment with L-asparaginase in children with acute lymphoblastic leukemia. BioMed Res Int 2014; 2014: 945860
• 25 Koenig H, Patel A. Biochemical basis for fluorouracil neurotoxicity. The role of Krebs cycle inhibition by fluoroacetate. Arch Neurol 1970; 23 (02) 155-160
• 26 Cohn RM, Roth KS. Hyperammonemia, bane of the brain. Clin Pediatr (Phila) 2004; 43 (08) 683-689
• 27 Kohn MC, Tohmaz AS, Giroux KJ, Blumenthal GM, Feezor MD, Millington DS. Robustness of MetaNet graph models: predicting control of urea production in humans. Biosystems 2002; 65 (01) 61-78